An updated systematic review of pharmacological treatments for presbyopia

Andrzej Grzybowski; Laura Kapitanovaite; Reda Zemaitiene

doi:10.1016/j.aopr.2024.09.001

您当前的位置：

首页 >

文章列表页 >

An updated systematic review of pharmacological treatments for presbyopia

Review | 更新时间：2024-12-14

- An updated systematic review of pharmacological treatments for presbyopia
- An updated systematic review of pharmacological treatments for presbyopia
- 眼科实践与研究新进展 2024年4卷第4期页码：220-225
- 作者机构：
  
  1. ,Poznan,Poland
  2. Department of Ophthalmology, University of Warmia and Mazury,Olsztyn,Poland
  3. Department of Ophthalmology, Hospital of Lithuanian University of Health Sciences, Kaunas Clinics,Kaunas,Lithuania
  4. Department of Ophthalmology, Medical Academy, Lithuanian University of Health Sciences,Kaunas,Lithuania
- 作者简介：
- 基金信息：
- DOI：10.1016/j.aopr.2024.09.001
  中图分类号：
- 纸质出版日期：2024，
- 稿件说明：
移动端阅览
Andrzej Grzybowski, Laura Kapitanovaite, Reda Zemaitiene. An updated systematic review of pharmacological treatments for presbyopia[J]. 眼科实践与研究新进展, 2024,4(4):220-225.

ANDRZEJ GRZYBOWSKI, LAURA KAPITANOVAITE, REDA ZEMAITIENE. An updated systematic review of pharmacological treatments for presbyopia. [J]. Aopr, 2024, 4(4): 220-225.
Andrzej Grzybowski, Laura Kapitanovaite, Reda Zemaitiene. An updated systematic review of pharmacological treatments for presbyopia[J]. 眼科实践与研究新进展, 2024,4(4):220-225. DOI： 10.1016/j.aopr.2024.09.001.

ANDRZEJ GRZYBOWSKI, LAURA KAPITANOVAITE, REDA ZEMAITIENE. An updated systematic review of pharmacological treatments for presbyopia. [J]. Aopr, 2024, 4(4): 220-225. DOI： 10.1016/j.aopr.2024.09.001.

摘要

Abstract

BackgroundPresbyopia

a common age-related condition affecting near vision

impacts over a billion people worldwide. The aim of this paper is to review the main reports and results of clinical trials

comparing the newest pharmacological treatment options for presbyopia

their mechanisms of action

and possible side effects.Main textPharmacological approaches

involving eye drops that target the underlying mechanisms of presbyopia

have gained growing interest. Two key pharmacological agents in this field are miotics and lens softeners. Miotics enhance near vision temporarily by creating a pinhole effect

though they may cause side effects and are under further investigation for long-term use with ongoing research also exploring the potential benefits of combining them with other drugs to improve outcomes and reduce adverse reactions. Lens softeners

on the other hand

aim to restore the flexibility of the lens

addressing one of the primary causes of presbyopia. Despite early trials

further development of lens softeners has been suspended. A notable advancement in this field is the recent FDA approval of 1.25% and 0.4% pilocarpine

a miotic agent

for presbyopia treatment. This milestone highlights the growing interest in pharmacological solutions for presbyopia

with several new drugs and their combinations currently being investigated for potential FDA approval.Conclusionspharmacological treatments

particularly miotics like pilocarpine

represent a promising alternative to conventional methods for managing presbyopia. Continued research into these treatments

especially combinations of drugs

may offer more effective and convenient options for presbyopia patients in the future.

关键词

Keywords

PresbyopiaPresbyopia treatmentMedicalPharmacological presbyopia treatment

references

1 J.S. Wolffsohn, L.N. DaviesPresbyopia: effectiveness of correction strategies Prog Retin Eye Res, 68 (Jan. 2019), pp. 124-143, 10.1016/J.PRETEYERES.2018.09.004

2 G. Benozzi, C. Perez, J. Leiro, S. Facal, B. OrmanPresbyopia treatment with eye drops: an eight year retrospective study Transl Vis Sci Technol, 9 (7) (Jun. 2020), p. 25, 10.1167/tvst.9.7.25

3 D.H. Chang, G.O. Waring, M. Hom, M. BarnettPresbyopia treatments by mechanism of action: a new classification system based on a review of the literature Clin Ophthalmol, 15 (Sep. 2021), pp. 3733-3745, 10.2147/OPTH.S318065

4 J.A. Katz, et al.Presbyopia – a review of current treatment options and emerging therapies Clin Ophthalmol, 15 (May 2021), pp. 2167-2178, 10.2147/OPTH.S259011

5 Vuity - pilocarpine ophthalmic solution for presbyopia Med Lett Drugs Ther, 64 (1643) (Feb. 2022), pp. 17-18

6 An Evaluation of the Safety of CSF-1 in Presbyopic Subjects,” Clinicaltrials.gov. Accessed: Mar. 24, 2024. [Online]. Available: https://clinicaltrials.gov/study/NCT05393895.

7 A. Grzybowski, V. RuamviboonsukPharmacological treatment in presbyopia J Clin Med, 11 (5) (Mar. 2022), p. 1385, 10.3390/jcm11051385

8 M.J. Page, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ (Mar. 2021), p. n71, 10.1136/bmj.n71

9 A. Grzybowski, A. Markeviciute, R. ZemaitieneA review of pharmacological presbyopia treatment Asia-Pacific Journal of Ophthalmology, 9 (3) (May 2020), pp. 226-233, 10.1097/APO.0000000000000297

10 M.S. Korenfeld, et al.Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial Eye, 35 (12) (Dec. 2021), pp. 3292-3301, 10.1038/s41433-020-01391-z

11 Novartis drops presbyopia drug acquired with Encore Vision,” https://pharmaphorum.com/. Accessed: March. 24, 2024. [Online]. Available: https://pharmaphorum.com/news/novartis-drops-presbyopia-drug-acquired-with-encore-vision.

12 Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (OPSIS),” Clinicaltrials.gov. Accessed: Mar. 24, 2024. [Online]. Available: https://clinicaltrials.gov/study/NCT05665387.

13 SantenPipeline development status (clinical stage) [Online]. Available: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.santen.com/content/dam/santen/global/pdf/en/business/pipeline.pdf (2024), Accessed 26th Mar 2024

14 CLARITY Phase 3 Topline Results.” Accessed: April. 15, 2024. [Online]. Available: https://ir.lenz-tx.com/news-events/presentations.

15 V. Panarese, M. MoshirfarPilocarpine [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/24862599 (2024)

16 H. Beasley, F.T. FraunfelderRetinal detachments and topical ocular miotics Ophthalmology, 86 (1) (Jan. 1979), pp. 95-98, 10.1016/S0161-6420(79)35529-4

17 Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia,” Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https://clinicaltrials.gov/study/NCT05431543.

18 E.A. Eton, P.Y. Zhao, M.W. Johnson, R.C. Rao, M.J. HuvardRhegmatogenous retinal detachment after initiation of pilocarpine hydrochloride ophthalmic solution 1.25% for treatment of presbyopia Retin Cases Brief Rep, 18 (1) (Jan. 2024), pp. 98-100, 10.1097/ICB.0000000000001309

19 L. Amarikwa, S.M. Michalak, S. Caul, P. Mruthyunjaya, E. RahimyVitreofoveal traction associated with pilocarpine for presbyopia Ophthalmic Surg Lasers Imaging Retina, 53 (7) (Jul. 2022), pp. 410-411, 10.3928/23258160-20220629-01

20 R. Rios Gonzalez, V.M. Villegas, M. BlasiniBilateral vitreomacular traction syndrome associated with topical pilocarpine 1% ophthalmic solution Am J Ophthalmol Case Rep, 30 (Jun. 2023), Article 101834, 10.1016/j.ajoc.2023.101834

21 T.J. Zimmerman, T.M. WheelerSide effects and ways to avoid them Ophthalmology, 89 (1) (Jan. 1982), pp. 76-80, 10.1016/S0161-6420(82)34866-6

22 F. Vejarano, J. Alió, R. Iribarren, C. LançaNon-miotic improvement in binocular near vision with a topical compound formula for presbyopia correction Ophthalmol Ther, 12 (2) (Apr. 2023), pp. 1013-1024, 10.1007/s40123-023-00648-6

23 Ocuphire Pharma announces submission of new drug application to FDA for Nyxol eye drops for reversal of mydriasis. News release.,” Ocuphire Pharma. . Accessed: March. 30, 2024. [Online]. Available: https://www.ocuphire.com/news-media/press-releases/detail/393/ocuphire-pharma-announces-submission-of-new-drug.

24 A. Abdelkader, H.E. KaufmanClinical outcomes of combined versus separate carbachol and brimonidine drops in correcting presbyopia Eye and Vision, 3 (1) (Dec. 2016), p. 31, 10.1186/s40662-016-0065-3

25 C. Kubo, R. SuzukiInvolvement of prejunctional alpha-adrenoceptor in bovine ciliary muscle movement J Ocul Pharmacol Therapeut, 8 (3) (Jan. 1992), pp. 225-231, 10.1089/jop.1992.8.225

26 Pharmacological Treatment of Presbyopia,” Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https://clinicaltrials.gov/study/NCT05564832#study-overview.

27 Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia (VEGA-2),” Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https://www.clinicaltrials.gov/study/NCT05646719.

28 Safety and Efficacy Study BRIMOCHOLTM PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia,” Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https://clinicaltrials.gov/study/NCT05270863.

29 Efficacy of Pilocarpine 1% in Presbyopia,” Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https://clinicaltrials.gov/study/NCT05578001.

30 Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia,” Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https://clinicaltrials.gov/study/NCT05294328.

31 “Phase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia (CLARITY),” Clinicaltrials.gov. Accessed: Mar. 24, 2024. [Online]. Available: https://clinicaltrials.gov/study/NCT05728944.

32 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia,” Clinicaltrials.gov. Accessed: Mar. 24, 2024. [Online]. Available: https://clinicaltrials.gov/study/NCT06045299.

33 Phase 3 Safety Study for the Treatment of Presbyopia Subjects,” Clinicaltrias.gov. Accessed: March. 24, 2024. [Online]. Available: https://clinicaltrials.gov/study/NCT05753189.

34 “Phase 3 evaluation of the safety and efficacy of LNZ101 for the treatment of presbyopia (CLARITY),” Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https://clinicaltrials.gov/study/NCT05656027.

35 Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia,” Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https://clinicaltrials.gov/study/NCT05936489.

36 “Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia,” Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https://clinicaltrials.gov/study/NCT06270030.

37 C.W. Lievens, M.M. Hom, E.B. McLaurin, J. Yuan, E. Safyan, H. LiuPilocarpine HCl 1.25% for treatment of presbyopia after laser vision correction: pooled analysis of two phase 3 randomized trials (GEMINI 1 and 2) J Cataract Refract Surg, 50 (1) (Jan. 2024), pp. 57-63, 10.1097/j.jcrs.0000000000001313

38 S. Kannarr, et al.Safety and efficacy of twice-daily pilocarpine HCl in presbyopia: the Virgo phase 3, randomized, double-masked, controlled study Am J Ophthalmol, 253 (Sep. 2023), pp. 189-200, 10.1016/j.ajo.2023.05.008

39 E. Holland, et al.Efficacy and safety of CSF-1 (0.4% pilocarpine hydrochloride) in presbyopia: pooled results of the NEAR phase 3 randomized, clinical trials Clin Therapeut, 46 (2) (Feb. 2024), pp. 104-113, 10.1016/j.clinthera.2023.12.005

40 H. Al-khersan, H.W. Flynn, J.H. TownsendRetinal detachments associated with topical pilocarpine use for presbyopia Am J Ophthalmol, 242 (Oct. 2022), pp. 52-55, 10.1016/j.ajo.2022.05.011

41 H. Ishikawa, L. DeSANTIS, P.N. PatilSelectivity of muscarinic agonists including (±)-Aceclidine and antimuscarinics on the human intraocular muscles J Ocul Pharmacol Therapeut, 14 (4) (Aug. 1998), pp. 363-373, 10.1089/jop.1998.14.363

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

The effects of premium intraocular lenses on presbyopia treatments